Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average - Should You Sell?
Oramed Pharmaceuticals (NASDAQ:ORMP) shares fell below their 200-day moving average of $2.30, trading at $2.12 with a volume of 21,385 shares. The company reported a loss of $0.19 EPS, missing estimates by $0.16, with quarterly revenue of $2 million. Analysts have downgraded the stock from "hold" to "sell." Institutional investors hold 12.73% of the stock, with several hedge funds increasing their positions recently. Oramed focuses on diabetes treatment through oral insulin capsules and other polypeptide delivery methods.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.30 and traded as low as $2.11. Oramed Pharmaceuticals shares last traded at $2.12, with a volume of 21,385 shares trading hands.
Get Oramed Pharmaceuticals alerts:
Analyst Ratings Changes
Separately, Wall Street Zen cut Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th.
Get Our Latest Stock Report on ORMP
Oramed Pharmaceuticals Stock Performance
The stock's fifty day moving average is $2.21 and its 200 day moving average is $2.30. The stock has a market cap of $86.60 million, a P/E ratio of 19.27 and a beta of 1.65.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The company had revenue of $2.00 million for the quarter. Equities research analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current year.
Hedge Funds Weigh In On Oramed Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in ORMP. BML Capital Management LLC raised its position in shares of Oramed Pharmaceuticals by 14.3% in the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock valued at $6,464,000 after purchasing an additional 376,841 shares during the period. Boothbay Fund Management LLC raised its position in shares of Oramed Pharmaceuticals by 2.0% in the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after purchasing an additional 16,857 shares during the period. Peapod Lane Capital LLC raised its position in shares of Oramed Pharmaceuticals by 11.0% in the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares during the period. 12.73% of the stock is owned by institutional investors.
Oramed Pharmaceuticals Company Profile
(Get Free Report)Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Recommended Stories
- Five stocks we like better than Oramed Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Workday Stock Price Implosion: An Automatic Buy for AI Investors
- The 3 Best Blue-Chip Stocks to Buy Now
- MercadoLibre Is Soaring—Should You Wait for a Better Entry?
- What is the Nikkei 225 index?
- Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
